[Antitumor activities of ME 2303 on human gastrointestinal cancer xenografted to nude mice].
The antitumor activity of ME 2303 was evaluated on 3 human stomach and 3 colon cancers xenografted to nude mice, which were established in our laboratory. The activity was compared with that of doxorubicin in terms of the inhibition of tumor growth and the histopathological changes. The dosage of ME 2303 was 35 or 50 mg/kg and that of doxorubicin was 5 mg/kg. Both drugs were administered intravenously 4 times at 5-day intervals. Thirty-five mg/kg of ME 2303 was effectively inhibited tumor growth against 3 lines, with marked efficacy against 2 lines. On the other hand, 50 mg/kg of ME 2303 was also effective against 4 lines tested (2 each of gastric and colorectal cancers), with marked efficacy against 3. In all, ME 2303 was more effective than doxorubicin except one of stomach cancer. The histopathological findings also revealed that 35 mg/kg of ME 2303 was equal or slightly superior to doxorubicin in efficacy. The side effects of ME 2303 such as weight loss were as mild as those with doxorubicin, except in the female mice administered 30 mg/kg of ME 2303 and no other adverse effect was observed. ME 2303 seems promising for clinical application in human since the increased efficacy in nude mice human xenograft might be found after more adequate modification of the dosage and administration schedule.